Abstract
Cells in the gastrointestinal tract secrete several hormones that stimulate insulin secretion, one of which is glucagon-like peptide (GLP-1). Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes. One such compound, exenatide (Byetta), has recently become available, and others are in clinical development.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 382-389 |
| Number of pages | 8 |
| Journal | Cleveland Clinic Journal of Medicine |
| Volume | 73 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2006 |
| Externally published | Yes |
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'New therapies for type 2 diabetes based on glucagon-like peptide 1'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS